Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

Published:2021-10 Issue: Volume: Page:
ISSN:2287-8882
Container-title:Prostate International
language:en
Short-container-title:Prostate International

Author:

Yamada Shigetomo,Shiota Masaki^ORCID,Blas Leandro^ORCID,Matsumoto Takashi,Kashiwagi Eiji,Takeuchi Ario,Inokuchi Junichi^ORCID,Shiga Ken-ichiro,Yokomizo Akira^ORCID,Eto Masatoshi^ORCID

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer;Shiota;Int J Urol,2016

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study;Scientific Reports;2024-08-27

2. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

3. Does androgenic alopecia aggravate the risk of prostate cancer? Evidence from Mendelian randomization;Prostate International;2024-06

4. The impact of obesity and sexual behavior on prostate cancer risk is mediated by testosterone levels: a mendelian randomization study and mediation analysis;Prostate International;2024-06

5. Abiraterone acetate versus enzalutamide against chemo-naïve castration resistant prostate cancer with full dose induction;2024-04-18